Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 11/08/23
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ETBusiness Wire • 11/01/23
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ETBusiness Wire • 10/10/23
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in GlioblastomaBusiness Wire • 10/03/23
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid TumorsBusiness Wire • 09/25/23
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin's LymphomasBusiness Wire • 09/18/23
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual MeetingBusiness Wire • 08/31/23
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint InhibitorsBusiness Wire • 08/28/23
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRTBusiness Wire • 08/14/23
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 08/09/23
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ETBusiness Wire • 08/02/23